Advice
following a re-submission:
capsaicin (Qutenza®) is accepted for restricted use within NHS Scotland.
Indication under review: For the treatment of peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain.
SMC restriction: to use in patients who have not achieved adequate pain relief from, or have not tolerated, conventional first and second line treatments.
A phase IV, open-label, randomised, controlled study showed that capsaicin patch was non-inferior to an oral analgesic in adult patients with peripheral neuropathic pain.
Download detailed advice176KB (PDF)
Medicine details
- Medicine name:
- capsaicin (Qutenza)
- SMC ID:
- 673/11
- Indication:
- For the treatment of peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain.
- Pharmaceutical company
- Astellas Pharma Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Resubmission
- Status
- Restricted
- Date advice published
- 13 October 2014